Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Other Non-Current Liabilities of $1.3 billion for Q1 2026, up 31.88% year-over-year from $951.9 million in Q1 2025, and down 1.11% quarter-over-quarter from $1.3 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 31.88% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 31.88% YoY), while the FY2025 annual figure was $1.3 billion, up 25.12% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.3 billion, down from $1.3 billion in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $1.3 billion in Q4 2025, with the low at $115.7 million in Q3 2022.
- The 5-year median for Other Non-Current Liabilities is $876.8 million (2024), against an average of $815.6 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities rose 6.66% in 2022, then surged 651.34% in 2023.
- Vertex Pharmaceuticals' Other Non-Current Liabilities stood at $685.8 million in 2022, then climbed by 27.98% to $877.7 million in 2023, then climbed by 15.6% to $1.0 billion in 2024, then advanced by 25.12% to $1.3 billion in 2025, then fell by 1.11% to $1.3 billion in 2026.
- Business Quant data shows VRTX's Other Non-Current Liabilities at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.26 Bn |
| Mar 31, 2026 | 1.26 Bn |
| Dec 31, 2025 | 1.27 Bn |
| Sep 30, 2025 | 1.23 Bn |
| Jun 30, 2025 | 1.20 Bn |
| Mar 31, 2025 | 951.90 Mn |
| Dec 31, 2024 | 1.01 Bn |
| Sep 30, 2024 | 933.30 Mn |
| Jun 30, 2024 | 876.80 Mn |
| Mar 31, 2024 | 853.60 Mn |
| Dec 31, 2023 | 877.70 Mn |
| Sep 30, 2023 | 869.30 Mn |
| Jun 30, 2023 | 759.30 Mn |
| Mar 31, 2023 | 726.50 Mn |
| Dec 31, 2022 | 685.80 Mn |
| Sep 30, 2022 | 115.70 Mn |
| Jun 30, 2022 | 129.80 Mn |
| Mar 31, 2022 | 117.40 Mn |
| Dec 31, 2021 | 303.30 Mn |
| Sep 30, 2021 | 108.47 Mn |